Freenome is developing a suite of blood-based, single-cancer screening tests for the purpose of detecting disease at its earliest and most treatable stages. They use a proprietary artificial intelligence-enabled “multiomics” approach that integrates tumor derived and immune analytes to assess the presence of a single cancer type. The company’s lead asset, a blood-based “liquid biopsy” test for colorectal cancer (CRC), has the potential to greatly expand access and compliance with recommended screening schedules. In the United States, there are over 100 million patients over the age of 45 that would benefit from such a test, representing a $14B annual opportunity. In addition to CRC, Freenome is currently developing liquid biopsies to detect prostate and pancreatic cancers. Freenome’s well-defined CRC go-to-market, regulatory and reimbursement strategies position them effectively to make inroads into this market, and their clinical machine learning feedback loop allows them to use CRC as a beachhead for rapid expansion into the broader cancer screening market.